4月25日 - ** 制药商艾伯维ABBV.N股价盘前上涨2.7%至185.3美元
** 艾伯维（AbbVie）将其2025年的盈利预期上调至 (link)，原因是其较新的免疫学药物Skyrizi和Rinvoq的销售好于预期，帮助其超过了季度盈利预期。
** 公司预计年度调整后利润为每股 12.09 美元至 12.29 美元，高于此前预计的 11.99 美元至 12.19 美元。
** ABBV 第一季度每股收益为 2.46 美元第一季度每股收益为2.46美元 ，分析师平均预期为2.38美元。
** 截至上一交易日收盘，ABBV股价累计上涨1.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.